Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen other Residual Products (8-K Schedule) — Worldwide growth YoY (%) (%)
Form 8-K Product Sales Detail Schedule
Latest, Q2 2026
5.0%
Period ended Jun 30, 2026
Change on a year earlier
+17.0 pts
-12.0% in Q2 2025
History
32 quarters
Since Q4 2017
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen Other Residual Products (8-K Schedule) — Worldwide growth YoY (%) (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_other_8k_yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.